SCHEMBL3366527

SCHEMBL3366527

CN1CCN(C(=O)CCc2ccc(S(=O)(=O)N(CC(=O)NN=C3C(=O)Nc4ccccc43)c3ccc(Cl)cc3)cc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.45
ALDH1A1 P00352 8/20 0.45
KDM4E B2RXH2 5/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.42
TSHR P16473 1/20 0.41
OXTR P30559 5/20 0.39
AVPR1A P37288 4/20 0.39
AVPR2 P30518 1/20 0.39
AVPR1B P47901 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
POLB P06746 1/20 0.38
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3366436 1.00 RAB9A (0.45) RAB9AALDH1A1KDM4EMEN1KMT2A
SCHEMBL3365025 0.86 OXTR (0.49) RAB9AALDH1A1KDM4EMEN1KMT2A
SCHEMBL3365022 0.86 OXTR (0.49) RAB9AALDH1A1KDM4EMEN1KMT2A
SCHEMBL3366368 0.84 OXTR (0.57) RAB9AALDH1A1MEN1KMT2ATSHR
SCHEMBL3366380 0.84 OXTR (0.57) RAB9AALDH1A1MEN1KMT2ATSHR
SCHEMBL3366411 0.82 MEN1 (0.51) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL5641723 0.82 MEN1 (0.51) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL3366414 0.82 MEN1 (0.51) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL3365642 0.82 OXTR (0.54) RAB9AALDH1A1KDM4EMEN1KMT2A
SCHEMBL3365636 0.82 OXTR (0.54) RAB9AALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1335901-B1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES MERCK SERONO SA (CH) 2010-04-14 EP claimed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US claimed
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives MERCK SERONO SA (CH) 2004-04-15 US claimed
EP-1335901-B1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES MERCK SERONO SA (CH) 2010-04-14 EP disclosed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US disclosed
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives MERCK SERONO SA (CH) 2004-04-15 US disclosed
EP-1335901-A1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2003-08-20 EP disclosed
WO-2002032864-A1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives OXTR, AVPR2, OPRL1 RAB9A 2096/4885ALDH1A1 2629/4885KDM4E 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.